Maxigen Biotech Reports September Revenue of NT$88.1M
Maxigen Biotech Inc. reported September revenue of NT$88,087,000, an increase from NT$65,117,000 in the previous year. For the January-September period, revenue was NT$632,257,000, up from NT$586,858,000 in the prior year.
Maxigen Biotech Inc. reported September revenue of NT$88,087,000 for 2026, compared with NT$65,117,000 for 2025, according to Taiwan Stock Exchange figures in New Taiwan dollars. For Jan-Sep, revenue was NT$632,257,000 in 2026 versus NT$586,858,000 in 2025.